DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/6t98xw/ankylosing) has announced the addition of the "Ankylosing Spondylitis Pipeline Highlights - 2016" report to their offering.
Ankylosing Spondylitis Pipeline Highlights - 2016, provides most up-to-date information on key pipeline molecules in the global Ankylosing Spondylitis market. It covers emerging therapies for Ankylosing Spondylitis in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
Clinical Trial Stages:
- The report provides Ankylosing Spondylitis pipeline molecules by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
Drug Mechanism Classes:
- The report provides Ankylosing Spondylitis pipeline molecules by their dominant mechanism of action. This helps executives categorize molecules based on their drug class and also assess the strengths and weaknesses of compounds.
- The report provides Ankylosing Spondylitis pipeline molecules by the company.
Short-term Launch Highlights:
- Find out which Ankylosing Spondylitis pipeline products will be launched in the US and Ex-US till 2019.
- Ankylosing Spondylitis phase 3 clinical trial pipeline molecules
- Ankylosing Spondylitis phase 2 clinical trial pipeline molecules
- Ankylosing Spondylitis phase 1 clinical trial pipeline molecules
- Ankylosing Spondylitis preclinical research pipeline molecules
- Ankylosing Spondylitis discovery stage pipeline molecules
- Ankylosing Spondylitis pipeline molecules short-term launch highlights
For more information visit http://www.researchandmarkets.com/research/6t98xw/ankylosing